LATEST

• BUSINESS Taiho Moves Araris’ ADC into PI for Lymphoma in US
  April 30, 2026

• BUSINESS Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
  April 30, 2026

• REGULATORY MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
  April 28, 2026

• REGULATORY Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
  April 28, 2026

• BUSINESS Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
  April 28, 2026

• BUSINESS Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
  April 28, 2026

• COMMENTARY Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
  April 28, 2026

• BUSINESS Teikoku, Curedisc Ink Japan Deal for Disc Herniation Drug
  April 28, 2026

• BUSINESS FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
  April 28, 2026

• REGULATORY Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
  April 28, 2026

• BUSINESS Kyorin to Transfer Generics Unit to Daito-Led JV
  April 28, 2026

• BUSINESS Guardant360 Snags Japan OK as CDx for AZ’s Camizestrant
  April 28, 2026

• BUSINESS Meiji Begins Japan PI/II Trial of Rezurock in Pediatric GVHD
  April 28, 2026

• REGULATORY Zepbound in Line for OSA Approval after Key Panel Nod
  April 27, 2026

• REGULATORY LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
  April 27, 2026

• REGULATORY Takaichi Says Govt to Weigh Response to MFN Drug Pricing Policy
  April 27, 2026

• ORGANIZATION Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
  April 27, 2026

• REGULATORY Nitrosamines Found in Duloxetine, Diltiazem; Panel Sets Intake Limits
  April 27, 2026

• BUSINESS Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
  April 27, 2026

• REGULATORY Health Insurance Reform Bill Clears Lower House Committee, Draws Backlash
  April 27, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• …
• Next ›
• 最終 »